GoodRx(US:GDRX)2025-11-04 21:31Financial Performance - Revenue for the three months ended September 30, 2025, was $196.0 million, a slight increase from $195.3 million in the same period of 2024[115] - Net income for the same period was $1.1 million, with a net income margin of 0.6%, down from $4.0 million and 2.0% in the prior year[115] - Adjusted EBITDA for the three months ended September 30, 2025, was $66.3 million, representing an Adjusted EBITDA Margin of 33.8%, compared to $65.0 million and 33.3% in the same period of 2024[115] - The company reported a revenue increase to $602.1 million for the nine months ended September 30, 2025, compared to $593.7 million in the same period of 2024[115] - Net income for the nine months ended September 30, 2025, was $25.0 million, with a net income margin of 4.2%, up from $9.7 million and 1.6% in the prior year[115] - Adjusted EBITDA for the nine months ended September 30, 2025, was $205.5 million, with an Adjusted EBITDA Margin of 34.1%, compared to $193.2 million and 32.5% in the same period of 2024[115] - Net income for Q3 2025 was $1.1 million, down from $4.0 million in Q3 2024, resulting in a net income margin of 0.6% compared to 2.0%[121] - Operating income rose to $64.8 million, compared to $47.7 million in the prior year, reflecting improved operational efficiency[146] - Net income for the nine months ended September 30, 2025, was $25.0 million, significantly up from $9.7 million in 2024, marking a year-over-year increase of 159%[146] Consumer Metrics - Monthly Active Consumers decreased to 5.4 million in Q3 2025 from 6.6 million in Q3 2024, reflecting a year-over-year decline[112] - Subscription plans as of September 30, 2025, totaled 671,000, a decrease from 701,000 in the same period of 2024[114] - Subscription revenue decreased by $0.6 million, or 3%, year-over-year, with 671 thousand subscription plans as of September 30, 2025, down from 701 thousand a year earlier[132] Revenue Breakdown - Prescription transactions revenue decreased by $13.1 million, or 9%, year-over-year, primarily due to a decline in Monthly Active Consumers[131] - Pharma manufacturer solutions revenue increased by $15.2 million, or 54%, year-over-year, driven by organic growth and market expansion[133] - Prescription transactions revenue decreased by $13.3 million, or 3%, year-over-year, while pharma manufacturer solutions revenue increased by $27.9 million, or 35%[146] Expenses and Costs - General and administrative expenses rose by $6.4 million, or 25%, year-over-year, mainly due to a $5.5 million estimated loss related to ongoing litigation[137] - Total costs and operating expenses for Q3 2025 were $181.4 million, an increase from $174.8 million in Q3 2024[127] - Sales and marketing expenses decreased by $20.3 million, or 7%, year-over-year, largely due to reduced stock-based compensation and third-party marketing expenses[151] - General and administrative expenses decreased by $4.3 million, or 5%, primarily due to a reduction in estimated legal settlement expenses[152] - Depreciation and amortization expenses increased by $11.6 million, or 23%, year-over-year, reflecting higher asset utilization and investment[153] Cash Flow and Investments - Cash and cash equivalents as of September 30, 2025, totaled $273.5 million, with an additional $80.2 million available under a revolving credit facility[156] - Net cash provided by operating activities decreased by $4.1 million year-over-year, primarily due to increased cash outflows from changes in operating assets and liabilities[163] - Net cash used in investing activities increased by $34.5 million, driven by a $30.0 million increase in cash paid for business acquisitions[164] Strategic Initiatives - The company acquired ScriptDrop, Inc. for $13.5 million in cash on October 16, 2025, enhancing its prescription delivery capabilities[108] - The company plans to expand its condition-specific subscription programs into additional conditions before the end of 2025[103]